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Attempts to treat patients with tumor-reactive or viral-spe-
cific cytotoxic T lymphocytes (CTLs) have been limited
due to the difficulty of isolating and expanding function-
ally active T cells present in low numbers in the peripheral
blood. Recently developed MHC/peptide multimers
mimic T cell receptor (TCR) ligands and, therefore, allow
visualization and isolation of antigen-specific CTLs. How-
ever, the persistence of multimers leads to prolonged TCR
signaling and subsequently to overstimulation and cell
death. We have generated a new type of MHC/peptide
multimers, termed streptamers, which can be dissociated
from the TCR. In the mouse model, the dissociation of
streptamers from the TCR, prevents T cells from multimer-
induced cell death (Knabel et al. Nature Med 2002, 8:631).
In this study, we investigate the efficacy of reversible HLA/
peptide multimers for isolation of human antigen-specific
T cells. Melan-A and CMV have been chosen as represent-
ative tumor-associated and viral antigen (Ag), respec-
tively. Specificity and reversibility of A2/CMV and A2/
Melan-A streptamers was documented by staining of Ag-
specific T cell clones and loss of staining after streptamer
removal. Streptamer-stained Ag-specific T cells remained
functionally active following dissociation, whereas lytic
function of T cells was impaired in the presence of non-
reversible multimers (tetramers). Furthermore,
CMVpp65(495–503)-specific T cells were streptamer- or
tetramer-sorted from HLA-A2-positive, CMV-seropositive
donors either directly out of the blood or following repet-
itive peptide stimulations in vitro. Both attempts success-
fully led to the isolation of CMV-specific CTLs that were
cloned by limiting dilution. Clonal proliferation was
superior for CMV-specific streptamer-sorted T cells com-
pared to tetramer-sorted T cells. CMV-specific T cell clones
isolated with streptamers and tetramers displayed a simi-
lar TCR repertoire and avidity. Growing CTL clones were
capable of lysing CMVpp65(495–503)-pulsed as well as
CMVpp65-transfected HLA-A2-positive target cells. For
isolation of melanoma-reactive CTLs, the modified
decapeptide Melan-A(26–35)A27L was chosen to con-
struct streptamers respective tetramers. Again, streptamer-
sorted Melan-A-specific CTL clones proliferated better
than tetramer-sorted CTL clones. The isolated Melan-A-
specific CTL clones displayed different TCR motifs, which
can be explained by the broad repertoire of Melan-A-spe-
cific T cells physiologically present in vivo. All Melan-
A(26–35)A27L-specific CTL clones crossreacted with the
naturally processed peptide Melan-A(27–35), but only
some CTL clones lysed HLA-A2-matched, Melan-A-
expressing melanoma cells. Of note, tumor recognition by
some streptamer-sorted CTL clones was superior to tumor
lysis by tetramer-sorted CTL clones. Our current experi-
ments focus on the isolation of T cells using reversible
multimers coupled with microbeads allowing us to sort
antigen-specific T cells under the guidelines of good man-
ufacturing practice. Clinical goal is the adoptive transfer of
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